According to a media release issued by a Canadian company called Profound Medical on August 16, the US Food and Drug Administration (FDA) has approved the use of a system called TULSA-PRO for the “ablation of prostate tissue”. There appears to be no relevant information on the FDA web site — as yet. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ablation, energy, Profound, thermal, transurethral, TULSA-PRO, ultrasound | Leave a comment »
For several years, Dr. Jelle Barentz in the Netherlands has been a prominent advocate for the idea that we might be able to use imaging methodologies (prostate “manograms”, like breast mammograms for women) to screen for risk of prostate cancer — either along with or instead of PSA testing. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biparametric, Diagnosis, fast, MRI, multiparametric, risk, scan | 2 Comments »
Patients who are initially diagnosed with primary Gleason pattern 5 localized prostate cancer (i.e., having Gleason scores of 5 + 5 = 10 and 5 + 4 = 9) are well understood to have very high-risk disease. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: 5, Gleason, medicine, pattern, precision, risk | 3 Comments »
In his latest epistle to the medical community on the MedPage Today web site, prostate cancer patient Howard Wolinsky writes about the need (or lack of need) for the use of gadolinium-containing contrast agents associated with the conduct of multiparametric MRI (mpMRI) scans. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: contrast, gadolinium, MRI, scan | 4 Comments »
Apparently the US Air Force (USAF) has become concerned that being a fighter pilot may increase risk for a diagnosis of prostate cancer. For those who are interested, here’s a link to the relevant article on the McClatchy news service. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Air Force, pilot, research, risk | 1 Comment »
Many men dislike digital rectal examinations (DREs) — for all sorts of reasons. However, a new study has again pointed out the value of the DRE in helping to establish clinical risk and the potential aggressiveness of a specific prostate cancer diagnosis in each individual patient. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: digital, DRE, examination, rectal | 7 Comments »
New research data on the epidemiology of advanced prostate cancer here in the US has confirmed something that has long been understood (albeit not previously as well documented). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: access, advanced, edpidemiology, risk | Leave a comment »
